[S-8] Molecular Partners AG American Employee Benefit Plan Registration

Rhea-AI Filing Summary

Molecular Partners AG has filed an S-8 registration statement to register securities related to three employee benefit plans: Performance Share Plan 2025 for Employees, Performance Share Plan 2025 for Management, and Restricted Share Plan 2025.

Key details of the filing:

• Filed on June 25, 2025 for Swiss-based biotech company trading under symbol MOLN
• Registration covers three distinct employee benefit plans introduced in 2025
• Company maintains principal executive offices in Zurich-Schlieren, Switzerland with U.S. presence in Cambridge, Massachusetts
• Filing incorporates by reference the company's annual report on Form 20-F for FY2024 and recent Form 6-K reports

The registration is signed by CEO Patrick Amstutz and includes signatures from the full board of directors, including Chairman William Burns. The company has appointed legal representation from Cooley LLP (US) and Homburger AG (Switzerland) for this filing. This registration enables Molecular Partners to offer equity-based compensation to both employees and management under these newly established plans.

Positive

• Implementation of new employee and management performance share plans for 2025, indicating structured approach to talent retention and alignment with shareholder interests
• Company maintains large accelerated filer status, suggesting significant market capitalization and trading volume

Negative

• None.

As filed with the Securities and Exchange Commission on June 25, 2025

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Molecular Partners AG

(Exact name of registrant as specified in its charter)

Switzerland						Not applicable
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

Wagistrasse 14
8952 Zurich-Schlieren
Switzerland

(Address of principal executive offices)

_____________________________________

Performance Share Plan 2025 – Employees

Performance Share Plan 2025 – Management

Restricted Share Plan 2025

____________________________________

(Full title of the plans)

Molecular Partners Inc.

245 Main Street

Cambridge, Massachusetts 02142

(781) 420 2361

(Name, address, including zip code, and telephone number of agent for service)

Copies to:

Divakar Gupta Ryan Sansom Brandon Fenn Cooley LLP 55 Hudson Yards New York, New York 10001 (212) 479 6000 Dieter Gericke Karin Mattle Homburger AG Prime Tower Hardstrasse 201CH-8005 Zurich Switzerland +41 43 222 16 59

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

o

Accelerated filer

o

Non-accelerated filer

Smaller reporting company

o

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  o

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participant in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.    Incorporation of Documents By Reference.

The following documents, which have been filed with the U.S. Securities and Exchange Commission (the “Commission”) by Molecular Partners AG (the “Registrant”), are hereby incorporated by reference into this Registration Statement:

(a) the Registrant’s annual report on Form 20-F (File No. 001-40488) for the fiscal year ended December 31, 2024, filed with the Commission on March 6, 2025; and

(b) the Registrant’s Reports of Foreign Private Issuer on Form 6-K, furnished to the SEC on May 15, 2025 (including the information contained in Exhibits 99.1 and 99.2 thereto, but excluding quotes of our management) and June 12, 2025 (including the information contained in Exhibit 99.1, but excluding quotes of our management); and

(c) the descriptions of the Registrant’s American Depositary Shares and Ordinary Shares contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on June 11, 2021 (File No. 001-40488) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, the Registrant is not incorporating by reference any documents, portions of documents, exhibits or other information that is deemed to have been furnished to, rather than filed with, the Commission. Under no circumstances shall any information subsequently furnished on Form 6-K be deemed incorporated herein by reference unless such Form 6-K expressly provides to the contrary.

Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4.    Description of Securities.

Not applicable.

Item 5.    Interests of Named Experts and Counsel.

Not applicable.

Item 6.    Indemnification of Directors and Officers.

Under Swiss law, subject to certain limitations, a corporation may indemnify and hold harmless directors and other persons entrusted with its management out of the assets of the corporation from and against actions, costs, charges, losses, damages and expenses which they or any of them may incur or sustain by or by reason of any act done, concurred in or omitted, in connection with the execution of their statutory duties, provided that such indemnity (if any) shall not extend to any matter in which any of said persons is found to have committed an intentional or grossly negligent breach of his or her duties.

In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses necessarily incurred by such employee in the proper execution of his or her duties under the employment agreement with the registrant.

The registrant has entered into indemnification agreements with each member of its board of directors and of its executive committee. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant, the registrant has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

Item 7.    Exemption From Registration Claimed.

Not applicable.

Item 8.    Exhibits.

Incorporated by Reference

Exhibit Number

Description

Schedule Form

File Number

Exhibit

Filing Date

4.1

Articles of Incorporation of the Registrant (as currently in effect)

20-F

001-40488

1.1

March 6, 2025

4.2

Deposit Agreement

20-F

001-40488

2.1

March 9, 2023

4.3

Form of American Depositary Receipt (included in Exhibit 4.2)

20-F

001-40488

2.2

March 9, 2023

4.4+

Description of Securities

5.1+

Opinion of Homburger AG

23.1+

Consent of KPMG AG, independent registered public accounting firm.

23.2+

Consent of Homburger AG (included in Exhibit 5.1).

24.1+

Power of Attorney (included on the signature page of this Form S-8).

99.1

Performance Share Plan 2025 – Employees

20-F

001-40488

4.20

March 6, 2025

99.2

Performance Share Plan 2025 – Management

20-F

001-40488

4.21

March 6, 2025

99.3

Restricted Share Plan 2025

20-F

001-40488

4.29

March 6, 2025

107+

Filing Fee Table

____________________________

+ Filed herewith.

Item 9.    Undertakings.

(a)     The undersigned Registrant hereby undertakes:

(1)     To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i)     To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii)     To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

(iii)     To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii)  do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2)     That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(3)     To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b)     The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c)     Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Zurich, Switzerland, on the 25th day of June, 2025.

MOLECULAR PARTNERS AG

By: /s/ Patrick Amstutz

Name: Patrick Amstutz

Title: Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Patrick Amstutz and Robert Hendriks, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

SIGNATURE

TITLE

DATE

/s/ Patrick Amstutz Patrick Amstutz, Ph.D.

Chief Executive Officer (Principal Executive Officer)

June 25, 2025

/s/ Robert Hendriks Robert Hendriks

SVP Finance (Principal Financial Officer and Principal Accounting Officer)

June 25, 2025

/s/ William Burns William M. Burns

Chairman of the Board of Directors

June 25, 2025

/s/ Agnete Fredriksen Agnete Fredriksen, Ph.D.

Director

June 25, 2025

/s/ Dominik Höchli Dominik Höchli, M.D.

Director

June 25, 2025

/s/ Steven Holtzman Steven Holtzman

Director

June 25, 2025

/s/ Sandip Kapadia Sandip Kapadia

Director

June 25, 2025

/s/ Vito J. Palombella Vito J. Palombella, Ph.D.

Director

June 25, 2025

/s/ Michael Vasconcelles Michael Vasconcelles, M.D.

Director

June 25, 2025

SIGNATURE OF THE AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Molecular Partners AG has signed this registration statement on Form S-8 on this 25th day of June, 2025.

MOLECULAR PARTNERS INC.

By: /s Patrick Amstutz                

Name: Patrick Amstutz

Title: Chief Executive Officer

FAQ

What employee benefit plans did MOLN register in its June 2025 S-8 filing?

MOLN registered three employee benefit plans in the S-8 filing: 1) Performance Share Plan 2025 - Employees, 2) Performance Share Plan 2025 - Management, and 3) Restricted Share Plan 2025.

Who are the key executives and board members that signed MOLN's S-8 registration in 2025?

Key signatories include Patrick Amstutz as CEO, Robert Hendriks as SVP Finance, and William M. Burns as Chairman of the Board. The filing was also signed by directors Agnete Fredriksen, Dominik Höchli, Steven Holtzman, Sandip Kapadia, Vito J. Palombella, and Michael Vasconcelles.

What indemnification provisions does MOLN offer its directors and officers?

Under Swiss law, MOLN may indemnify directors and management from actions and expenses related to their duties, but only if they haven't committed intentional or grossly negligent breaches. The company has entered into specific indemnification agreements with each board member and executive committee member, though SEC rules state such indemnification for Securities Act liabilities may be unenforceable.

What documents were incorporated by reference in MOLN's S-8 filing?

The filing incorporated: 1) Form 20-F annual report for FY2024 filed March 6, 2025, 2) Form 6-K reports from May 15, 2025 and June 12, 2025, and 3) descriptions of ADSs and Ordinary Shares from Form 8-A filed June 11, 2021.

Where is MOLN's principal executive office located?

MOLN's principal executive office is located at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland. The company also maintains a U.S. presence through Molecular Partners Inc. at 245 Main Street, Cambridge, Massachusetts 02142.